Biosimilar Uptake in Medicare Advantage vs Traditional Medicare.

Kozlowski, Steven; Kwist, Andrew; McEvoy, Rowan; Koirala, Nirabh; Chillarige, Yoganand; Kelman, Jeffrey A; Graham, David J

Kozlowski, Steven; Kwist, Andrew; McEvoy, Rowan; Koirala, Nirabh; Chillarige, Yoganand; Kelman, Jeffrey A; Graham, David J.

Afiliação

Kozlowski S; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Kwist A; Acumen LLC, Burlingame, California.
McEvoy R; Acumen LLC, Burlingame, California.
Koirala N; Acumen LLC, Burlingame, California.
Chillarige Y; Acumen LLC, Burlingame, California.
Kelman JA; Centers for Medicare & Medicaid Services, Washington, DC.
Graham DJ; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

JAMA Health Forum ; 4(12): e234335, 2023 Dec 01.

Article em En | MEDLINE | ID: mdl-38153810

This cross-sectional study uses Traditional Medicare and Medicare Advantage claims data to evaluate uptake of biosimilars relative to their reference products.

Assuntos

Medicamentos Biossimilares; Medicare Part C; Estados Unidos; Transporte Biológico

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicare Part C / Medicamentos Biossimilares País/Região como assunto: America do norte Idioma: En Revista: JAMA Health Forum Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google